Skip to main content

Table 2 Survival groups by favourable biomarker status

From: Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

Factor Short survival Long survival Unadjusted Adjustedc
ORa (95% CI) P b ORa (95% CI) P
BRAF
 Wildtype 10 (43) 13 (57) 2.8 (0.8-10) 0.11 4.5 (0.7-27) 0.10
 Mutation 13 (68) 6 (32) 1   1  
Ki67
 Low 9 (38) 15 (63) 5.8 (1.5-23) 0.013 26.1(2.0-344) 0.013
 High 14 (78) 4 (22) 1   1  
FOXP3
 Low 13 (65) 7 (35) 1 0.21 1 0.42
 High 10 (45) 12 (55) 2.2 (0.6-7.7)   1.9 (0.4-9.4)  
CD8
 Low 15 (68) 7 (32) 1 0.071 1 0.17
 High 8 (40) 12 (60) 3.2 (0.9-11)   3.0 (0.6-15)  
Number of favourable markers out of the above 4
 At least 3 4 (25) 12 (75) 8.1 (2.0-34) 0.004 19.4 (1.9-197) 0.012
 Less than 3 19 (73) 7 (27) 1   1  
  1. aOdds-ratio and 95% confidence interval estimated using unconditional logistic regression
  2. bWald test p-value
  3. cControlling for ulceration and LGLL